Using near real-time molecular surveillance to inform data-to-care in New York City

Lucia V. Torian1, Chi-Chi N. Udeagu1, Lisa A. Forgione1, Qiang Xia1, Joel O. Wertheim2, Kavita Misra1, Jamie Huang1, Jennifer Rakeman-Cagnol1, Michael A. Castro1, Susan Blank1, Sarah L. Braunstein1

1New York City Department of Health and Mental Hygiene, Long Island City, NY, USA,
2University of California San Diego La Jolla, CA, USA

BACKGROUND
Molecular HIV surveillance has been proposed as a tool to augment traditional partner services and data to care (D2C) activities by adding persons with genetically proximate viruses to the pool of named partners and social network members receiving public health intervention after a new diagnosis of HIV.

METHODS
The New York City Department of Health and Mental Hygiene conducted a demonstration project to determine whether early ascertainment of viral genetic proximity between newly diagnosed and prevalent cases was feasible and resulted in timely identification of and outreach to persons in transmission clusters identified by HIV-Trace, a genetic distance-based clustering tool. Persons newly diagnosed with HIV at the city’s 8 sexual health clinics (SHC) were the Index cases; their partial pol sequences were analyzed for pairwise concordance to those of 71,189 prevalent cases using a 1.5% genetic distance threshold. Clusters were inferred, and cluster data were not available at the time of the Index partner services interview. However, analysis performed against the prevalence pool yielded a total of 225 clusters containing 2,778 unique members. Clusters ranged in size from 2-155 persons with diagnosis dates from 1981-2018, of whom 147 (5%) were deemed to be potentially eligible for OOC and 108 (4%) for viremia services. 91% of cluster members were MSM; clusters were homogeneous with respect to age at diagnosis (median 26) and race/ethnicity but not by neighborhood of residence.

RESULTS
Between June 1, 2016, and June 25, 2018, whole blood specimens from 722 persons testing preliminary positive on point-of-care rapid HIV screening were submitted to the NYC Public Health Laboratory for confirmation and resistance testing, resulting in 526 interpretable genotypes. SHCs received resistance reports and sequences were posted a median of 10 days (IQR 8-15) after specimen draw date. Pairwise concordance analysis of the Index virus against the prevalence pool yielded a total of 225 clusters containing 2,778 unique members. Clusters ranged in size from 2-155 persons with diagnosis dates from 1981-2018, of whom 147 (5%) were deemed to be potentially eligible for OOC and 108 (4%) for viremia services. 91% of cluster members were MSM; clusters were homogeneous with respect to age at diagnosis (median 26) and race/ethnicity but not by neighborhood of residence.

CONCLUSION
Despite our optimized scenario (genotype ordered on day of diagnosis), cluster data were not available at the time of the Index partner services interview. However, analysis performed as soon as the sequence was posted allowed us to identify and prioritize for outreach previously diagnosed, genetically proximate OOC and in-care but viremic cluster members on a monthly basis, making it possible to achieve “near real-time” D2C for genetic partners.